Nothing Special   »   [go: up one dir, main page]

WO2004072265A3 - Methods for monitoring drug activities in vivo - Google Patents

Methods for monitoring drug activities in vivo Download PDF

Info

Publication number
WO2004072265A3
WO2004072265A3 PCT/US2004/004118 US2004004118W WO2004072265A3 WO 2004072265 A3 WO2004072265 A3 WO 2004072265A3 US 2004004118 W US2004004118 W US 2004004118W WO 2004072265 A3 WO2004072265 A3 WO 2004072265A3
Authority
WO
WIPO (PCT)
Prior art keywords
vivo
methods
genes
activities
monitoring
Prior art date
Application number
PCT/US2004/004118
Other languages
French (fr)
Other versions
WO2004072265A2 (en
Inventor
Michael Burczynski
Natalie Twine
Andrew J Dorner
William L Trepicchio
Original Assignee
Wyeth Corp
Michael Burczynski
Natalie Twine
Andrew J Dorner
William L Trepicchio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Michael Burczynski, Natalie Twine, Andrew J Dorner, William L Trepicchio filed Critical Wyeth Corp
Priority to CA002515677A priority Critical patent/CA2515677A1/en
Priority to AU2004210986A priority patent/AU2004210986A1/en
Priority to EP04710266A priority patent/EP1592811A2/en
Publication of WO2004072265A2 publication Critical patent/WO2004072265A2/en
Publication of WO2004072265A3 publication Critical patent/WO2004072265A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells can be modulated by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for monitoring drug activities in vivo.
PCT/US2004/004118 2003-02-11 2004-02-11 Methods for monitoring drug activities in vivo WO2004072265A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002515677A CA2515677A1 (en) 2003-02-11 2004-02-11 Methods for monitoring drug activities in vivo
AU2004210986A AU2004210986A1 (en) 2003-02-11 2004-02-11 Methods for monitoring drug activities in vivo
EP04710266A EP1592811A2 (en) 2003-02-11 2004-02-11 Methods for monitoring drug activities in vivo

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US44613303P 2003-02-11 2003-02-11
US60/446,133 2003-02-11
US45978203P 2003-04-03 2003-04-03
US60/459,782 2003-04-03
US53824604P 2004-01-23 2004-01-23
US60/538,246 2004-01-23

Publications (2)

Publication Number Publication Date
WO2004072265A2 WO2004072265A2 (en) 2004-08-26
WO2004072265A3 true WO2004072265A3 (en) 2005-03-03

Family

ID=32872756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/004118 WO2004072265A2 (en) 2003-02-11 2004-02-11 Methods for monitoring drug activities in vivo

Country Status (4)

Country Link
EP (1) EP1592811A2 (en)
AU (1) AU2004210986A1 (en)
CA (1) CA2515677A1 (en)
WO (1) WO2004072265A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP1588142A4 (en) 2002-11-21 2007-10-31 Wyeth Corp Methods for diagnosing rcc and other solid tumors
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
US20060194211A1 (en) * 2003-04-29 2006-08-31 Burczynski Michael E Methods for prognosis and treatment of solid tumors
WO2006097388A2 (en) * 2005-02-08 2006-09-21 Innogenetics N.V. Nucleic acid variants in the c1qr1 gene associated with altered innate immunity.
BRPI0613429A2 (en) 2005-07-14 2009-02-10 Takeda San Diego Inc histone deacetylase inhibitors
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AU2013206613B2 (en) * 2005-09-12 2017-03-02 Biontech Ag Identification of tumor-associated antigens for diagnosis and therapy
JP2010509909A (en) * 2006-11-16 2010-04-02 ジェントロン リミテッド ライアビリティー カンパニー Methods, systems, and compositions for cancer diagnosis
CN104313027B (en) 2009-08-11 2018-11-20 库尔纳公司 By inhibiting the natural antisense transcript of adiponectin (ADIPOQ) to treat adiponectin (ADIPOQ) related disease
EP2563764B1 (en) 2010-04-26 2015-02-25 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
WO2011137012A1 (en) 2010-04-27 2011-11-03 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
WO2011146300A1 (en) 2010-05-17 2011-11-24 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
WO2011156220A1 (en) 2010-06-08 2011-12-15 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2579873A4 (en) 2010-06-11 2013-11-27 Merck Sharp & Dohme Novel prolylcarboxypeptidase inhibitors
US20200277669A1 (en) * 2017-11-15 2020-09-03 The Translational Genomics Research Institute Biomarker proxy tests and methods for standard blood chemistry tests
CN112852964B (en) * 2021-03-08 2022-02-11 镇江市第一人民医院 Circular RNA hsa _ circ _0059707, specific amplification primer thereof and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040749A2 (en) * 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
WO2001081916A2 (en) * 2000-04-24 2001-11-01 Beth Israel Deaconess Medical Center, Inc. Methods of evaluating transplant rejection
WO2002040000A2 (en) * 2000-11-15 2002-05-23 Wyeth Use of cci-779 as an antineoplastic agent
WO2004048933A2 (en) * 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061144A2 (en) * 2001-01-31 2002-08-08 Whitehead Institute For Biomedical Research Brain tumor diagnosis and outcome prediction

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040749A2 (en) * 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
WO2001081916A2 (en) * 2000-04-24 2001-11-01 Beth Israel Deaconess Medical Center, Inc. Methods of evaluating transplant rejection
WO2002040000A2 (en) * 2000-11-15 2002-05-23 Wyeth Use of cci-779 as an antineoplastic agent
WO2004048933A2 (en) * 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Product Catalogue", January 2002, AFFYMETRIX, XP002295173 *
BURCZYNSKI ET AL.: "Pharmacogenomic expression profiling of renal cell carcinoma in a phase II trial of CCI-779: identification of surrogate markers of disease and predictors of outcome in the compartment of peripheral blood", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, November 2002 (2002-11-01), pages S51, XP002295167, ISSN: 0959-8049 *
DATABASE SOURCE 2 September 2004 (2004-09-02) *
DIPAOLA R S ET AL: "Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. JUL 1999, vol. 17, no. 7, July 1999 (1999-07-01), pages 2213 - 2218, XP002295169, ISSN: 0732-183X *
ELIT LAURIE: "CCI-779 Wyeth.", CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND : 2000) AUG 2002, vol. 3, no. 8, August 2002 (2002-08-01), pages 1249 - 1253, XP008037562, ISSN: 1472-4472 *
PERALBA JOSEP MARIA ET AL: "Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 AUG 2003, vol. 9, no. 8, 1 August 2003 (2003-08-01), pages 2887 - 2892, XP002295172, ISSN: 1078-0432 *
PERALBA JOSEP-MARIA ET AL: "Pharmacodynamic evaluation of the rapamycin ester CCI-779", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), & 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10, 2002, pages 1000 - 1001, XP001182924, ISSN: 0197-016X *
RININGER J A ET AL: "Differential gene expression technologies for identifying surrogate markers of drug efficacy and toxicity", DRUG DISCOVERY TODAY 01 DEC 2000 UNITED KINGDOM, vol. 5, no. 12, 1 December 2000 (2000-12-01), pages 560 - 568, XP002295171, ISSN: 1359-6446 *
SCHULZE-KOOPS H ET AL: "Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1).", CLINICAL AND EXPERIMENTAL IMMUNOLOGY. NOV 1996, vol. 106, no. 2, November 1996 (1996-11-01), pages 190 - 196, XP002295168, ISSN: 0009-9104 *
See also references of EP1592811A2 *
SU A I ET AL: "Molecular classification of human carcinomas by use of gene expression signatures", CANCER RESEARCH 15 OCT 2001 UNITED STATES, vol. 61, no. 20, 15 October 2001 (2001-10-15), pages 7388 - 7393, XP002295170, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2004072265A2 (en) 2004-08-26
AU2004210986A1 (en) 2004-08-26
EP1592811A2 (en) 2005-11-09
CA2515677A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
WO2004072265A3 (en) Methods for monitoring drug activities in vivo
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2004075865A3 (en) Selective modulation of tlr-mediated biological activity
WO2009092087A3 (en) Selective differentiation, identification, and modulation of human th17 cells
WO2008091835A3 (en) Implantable medical endoprostheses
WO2008036658A3 (en) Method and system for controlled infusion of therapeutic substances
WO2003074662A3 (en) SCDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2008070346A3 (en) Methods for treating pain with reduced nuasea and vomiting
WO2005016227A3 (en) Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
WO2010034015A3 (en) Modulating the alternative complement pathway
MXPA05012319A (en) Delivery of compounds with rehydrated blood cells.
WO2006074450A3 (en) Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
WO2008112898A3 (en) Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
WO2004094673A8 (en) Methods for monitoring drug activities in vivo
BRPI0412989A (en) pharmaceutical combination useful for stem cell mobilization
WO2004081229A3 (en) Use of bv8 and/or eg-vegf to promote hematopoiesis
WO2007002087A3 (en) Cdc6s as modifiers of the pten/akt pathway and methods of use
WO2007117572A3 (en) Optical coherence tomographic detection of cells and killing of the same
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2005002418A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2006099183A3 (en) Nek8s as modifiers of the pten/akt pathway and methods of use
WO2005003297A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004037990A3 (en) MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
WO2005090992A3 (en) Mptens as modifiers of the pten pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004710266

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2515677

Country of ref document: CA

Ref document number: 541700

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004210986

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004210986

Country of ref document: AU

Date of ref document: 20040211

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004210986

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004710266

Country of ref document: EP